Virginia Tech scientists have developed a cancer drug that increases the effectiveness of a common chemotherapy treatment and dramatically reduces devastating side effects, such as hair loss, nausea, and nerve pain. The new drug uses gold nanoparticles created by the biotech firm CytImmune Sciences to deliver paclitaxel — a commonly used chemotherapy drug — directly to a tumor. In early lab tests in treating mouse melanoma, a 2.5-milligram dose of paclitaxel delivered on Kingston’s gold nanoparticles vehicle was essentially as effective as a dose of 40 milligrams of paclitaxel by itself. The delivery method is expected to soon move toward clinical trial, said Kingston.
- KeViRx-UVA-ODU Collaborative SBIR Grant funded
- Paul Carlier, Chair of the VaDDC, Receives Grant to Study Promising Antimalarial Drugs
- Norwegian researchers have shown that a phosphatase (PRL-3) inhibitor developed by VaDDC Exec. Comm. member John Lazo might be useful to treat cancer
- Webster Santos, Virginia Tech drug researcher receives $2.2 million NIH grant to further develop “fat burning” molecule
- VaDDC Executive Committee Member, Beth Sharlow Receives Promotion at UVA